Global Fellows Research Academy

Henry Mugerwa

Nationality: Uganda
Institution: Joint Clinical Research Centre
Country of work: Uganda

What is your motivation for engaging in HIV cure and remission research?

Though great strides have been made in the management of HIV, there is a greater need to find a lasting solution to this problem. The cost of HIV care put strain on governments, the affected individuals and families in one way or another. The sustainability of HIV drugs for all that need treatment has always been a concern especially in the low resource countries. The emerging HIV resistant strains compounds the situation hence lasting solution in form of a cure is of essence. Working in an HIV care and Research organization gives me a great opportunity to contribute towards this.

What is your current area of research?

I am working on several HIV clinical trials that are being conducted at the institution as a co-investigator, Investigator of record or as a principal investigator. The major studies include the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) study which evaluated the second line option for those failing their first ART regimen, the Strategic Timing of Antiretroviral Treatment (START) study whose interim results contributed to the current WHO guideline of “Test and Treat” as well as the HIV reservoir study, a sub study within the START study. I am also working on some Pharma protocols that are evaluating the efficacy of some newer antiretroviral drugs that may be associated with less side effects but with similar or better efficacy to some of the current drugs.